{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T23:49:07Z","timestamp":1773791347096,"version":"3.50.1"},"reference-count":74,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite recent improvements in the treatment of early-stage disease, the blastic phase of chronic myeloid leukemia (CML) remains a therapeutic challenge. For imatinib-nai\u0308ve patients, imatinib provided encouraging hematologic and cytogenetic benefits; however, the vast majority of CML blast crisis cases today arise in patients already on imatinib-based therapy. Clonal evolution and duplication of the Philadelphia chromosome continue to be associated with blastic phase transformation, but recent studies have identified BCR\/ABL kinase domain mutations in 30%\u201340% of blast crisis patients. This implies that BCR-ABL\u2013targeted therapy might have influenced the molecular road map to blastic transformation. In this review, we will examine the effect of imatinib on primitive CML progenitors and how this might influence the pathophysiology of blast crisis. A rational framework for deciding how best to integrate stem cell transplantation, traditional chemotherapy, imatinib, and other BCR-ABL kinase inhibitors in the care of blast crisis patients will also be discussed.<\/jats:p>","DOI":"10.1182\/asheducation-2005.1.188","type":"journal-article","created":{"date-parts":[[2005,11,23]],"date-time":"2005-11-23T01:29:34Z","timestamp":1132709374000},"page":"188-194","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":35,"title":["Pathobiology of Lymphoid and Myeloid Blast Crisis and Management Issues"],"prefix":"10.1182","volume":"2005","author":[{"suffix":"Jr.","given":"Robert L.","family":"Ilaria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111704083346700_R1","doi-asserted-by":"crossref","unstructured":"Martin PJ, Najfeld V, Hansen JA, Penfold GK, Jacobson RJ, Fialkow PJ. Involvement of the B-lymphoid system in chronic myelogenous leukaemia. Nature. 1980;287:49\u201350.","DOI":"10.1038\/287049a0"},{"key":"2019111704083346700_R2","doi-asserted-by":"crossref","unstructured":"Salloukh HF, Laneuville P. Increase in mutant frequencies in mice expressing the BCR-ABL activated tyrosine kinase. Leukemia. 2000;14:1401\u20131404.","DOI":"10.1038\/sj.leu.2401855"},{"key":"2019111704083346700_R3","doi-asserted-by":"crossref","unstructured":"Canitrot Y, Lautier D, Laurent G, et al. Mutator phenotype of BCR-ABL transfected Ba\/F3 cell lines and its association with enhanced expression of DNA polymerase beta. Oncogene. 1999;18:2676\u20132680.","DOI":"10.1038\/sj.onc.1202619"},{"key":"2019111704083346700_R4","doi-asserted-by":"crossref","unstructured":"Brummendorf TH, Holyoake TL, Rufer N, et al. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. Blood. 2000;95:1883\u20131890.","DOI":"10.1182\/blood.V95.6.1883"},{"key":"2019111704083346700_R5","doi-asserted-by":"crossref","unstructured":"Sattler M, Verma S, Shrikhande G, et al. The BCR\/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem. 2000;275:24273\u201324278.","DOI":"10.1074\/jbc.M002094200"},{"key":"2019111704083346700_R6","doi-asserted-by":"crossref","unstructured":"Canitrot Y, Falinski R, Louat T, et al. p210 BCR\/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation. Blood. 2003;102:2632\u20132637.","DOI":"10.1182\/blood-2002-10-3207"},{"key":"2019111704083346700_R7","doi-asserted-by":"crossref","unstructured":"Deutsch E, Jarrousse S, Buet D, et al. Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells. Blood. 2003;101:4583\u20134588.","DOI":"10.1182\/blood-2002-10-3011"},{"key":"2019111704083346700_R8","doi-asserted-by":"crossref","unstructured":"Deutsch E, Dugray A, AbdulKarim B, et al. BCR-ABL down-regulates the DNA repair protein DNA-PKcs. Blood. 2001;97:2084\u20132090.","DOI":"10.1182\/blood.V97.7.2084"},{"key":"2019111704083346700_R9","doi-asserted-by":"crossref","unstructured":"Dierov J, Dierova R, Carroll M. BCR\/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint. Cancer Cell. 2004;5:275\u2013285.","DOI":"10.1016\/S1535-6108(04)00056-X"},{"key":"2019111704083346700_R10","unstructured":"Marktel S, Marin D, Foot N, et al. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. Haematologica. 2003;88:260\u2013267."},{"key":"2019111704083346700_R11","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, Keating MJ, Talpaz M, et al. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med. 1987;83:445\u2013454.","DOI":"10.1016\/0002-9343(87)90754-6"},{"key":"2019111704083346700_R12","doi-asserted-by":"crossref","unstructured":"Ahuja H, Bar-Eli M, Advani SH, Benchimol S, Cline MJ. Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proc Natl Acad Sci U S A. 1989;86:6783\u20136787.","DOI":"10.1073\/pnas.86.17.6783"},{"key":"2019111704083346700_R13","doi-asserted-by":"crossref","unstructured":"Sill H, Goldman JM, Cross NC. Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood. 1995;85:2013\u20132016.","DOI":"10.1182\/blood.V85.8.2013.bloodjournal8582013"},{"key":"2019111704083346700_R14","doi-asserted-by":"crossref","unstructured":"Sattler M, Griffin JD. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol. 2003;40:4\u201310.","DOI":"10.1053\/shem.2003.50034"},{"key":"2019111704083346700_R15","doi-asserted-by":"crossref","unstructured":"Melo JV, Deininger MW. Biology of chronic myelogenous leukemia\u2014signaling pathways of initiation and transformation. Hematol Oncol Clin North Am. 2004;18:545\u2013568, vii\u2013viii.","DOI":"10.1016\/j.hoc.2004.03.008"},{"key":"2019111704083346700_R16","doi-asserted-by":"crossref","unstructured":"Van Etten RA. Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. Leuk Res. 2004;28 Suppl 1:21\u201328.","DOI":"10.1016\/j.leukres.2003.10.005"},{"key":"2019111704083346700_R17","doi-asserted-by":"crossref","unstructured":"Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004;103:4010\u20134022.","DOI":"10.1182\/blood-2003-12-4111"},{"key":"2019111704083346700_R18","doi-asserted-by":"crossref","unstructured":"Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. 2003;101:690\u2013698.","DOI":"10.1182\/blood.V101.2.690"},{"key":"2019111704083346700_R19","doi-asserted-by":"crossref","unstructured":"Klucher KM, Lopez DV, Daley GQ. Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR\/ABL expression. Blood. 1998;91:3927\u20133934.","DOI":"10.1182\/blood.V91.10.3927"},{"key":"2019111704083346700_R20","doi-asserted-by":"crossref","unstructured":"Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood. 2003;101:4701\u20134707.","DOI":"10.1182\/blood-2002-09-2780"},{"key":"2019111704083346700_R21","doi-asserted-by":"crossref","unstructured":"Lugo TG, Pendergast A, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247:1079\u20131082.","DOI":"10.1126\/science.2408149"},{"key":"2019111704083346700_R22","doi-asserted-by":"crossref","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994\u20131004.","DOI":"10.1056\/NEJMoa022457"},{"key":"2019111704083346700_R23","doi-asserted-by":"crossref","unstructured":"Kantarjian H, Talpaz M, O\u2019Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004;103:2873\u20132878.","DOI":"10.1182\/blood-2003-11-3800"},{"key":"2019111704083346700_R24","doi-asserted-by":"crossref","unstructured":"Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399\u2013401.","DOI":"10.1126\/science.1099480"},{"key":"2019111704083346700_R25","doi-asserted-by":"crossref","unstructured":"Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7:129\u2013141.","DOI":"10.1016\/j.ccr.2005.01.007"},{"key":"2019111704083346700_R26","doi-asserted-by":"crossref","unstructured":"Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol. 2005;23:4100\u20134109","DOI":"10.1200\/JCO.2005.05.531"},{"key":"2019111704083346700_R27","doi-asserted-by":"crossref","unstructured":"Willis S, Lange T, Demehri S, et al. High sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but no response to therapy. Blood. 2005;106:2128\u20132137","DOI":"10.1182\/blood-2005-03-1036"},{"key":"2019111704083346700_R28","doi-asserted-by":"crossref","unstructured":"Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102:276\u2013283.","DOI":"10.1182\/blood-2002-09-2896"},{"key":"2019111704083346700_R29","doi-asserted-by":"crossref","unstructured":"Roche-Lestienne C, Lai JL, Darre S, Facon T, Preudhomme C. A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia. N Engl J Med. 2003;348:2265\u20132266.","DOI":"10.1056\/NEJMc035089"},{"key":"2019111704083346700_R30","doi-asserted-by":"crossref","unstructured":"Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer. 2003;3:895\u2013902.","DOI":"10.1038\/nrc1232"},{"key":"2019111704083346700_R31","doi-asserted-by":"crossref","unstructured":"Huntly BJ, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer. 2005;5:311\u2013321.","DOI":"10.1038\/nrc1592"},{"key":"2019111704083346700_R32","doi-asserted-by":"crossref","unstructured":"Elrick LJ, Jorgensen HG, Mountford JC, Holyoake TL. Punish the parent not the progeny. Blood. 2005;105:1862\u20131866.","DOI":"10.1182\/blood-2004-08-3373"},{"key":"2019111704083346700_R33","doi-asserted-by":"crossref","unstructured":"Gambacorti-Passerini C, Barni R, le Coutre P, et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR- ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst. 2000;92:1641\u20131650.","DOI":"10.1093\/jnci\/92.20.1641"},{"key":"2019111704083346700_R34","unstructured":"Gambacorti-Passerini C, Zucchetti M, Russo D, et al. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res. 2003;9:625\u2013632."},{"key":"2019111704083346700_R35","doi-asserted-by":"crossref","unstructured":"Widmer N, Colombo S, Buclin T, Decosterd LA. Functional consequence of MDR1 expression on imatinib intracellular concentrations. Blood. 2003;102:1142.","DOI":"10.1182\/blood-2003-03-0993"},{"key":"2019111704083346700_R36","doi-asserted-by":"crossref","unstructured":"Hegedus T, Orfi L, Seprodi A, Varadi A, Sarkadi B, Keri G. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta. 2002;1587:318\u2013325.","DOI":"10.1016\/S0925-4439(02)00095-9"},{"key":"2019111704083346700_R37","doi-asserted-by":"crossref","unstructured":"Dai H, Marbach P, Lemaire M, Hayes M, Elmquist WF. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther. 2003;304:1085\u20131092.","DOI":"10.1124\/jpet.102.045260"},{"key":"2019111704083346700_R38","doi-asserted-by":"crossref","unstructured":"Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood. 2003;101:2368\u20132373.","DOI":"10.1182\/blood.V101.6.2368"},{"key":"2019111704083346700_R39","doi-asserted-by":"crossref","unstructured":"Ozvegy-Laczka C, Hegedus T, Varady G, et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol. 2004;65:1485\u20131495.","DOI":"10.1124\/mol.65.6.1485"},{"key":"2019111704083346700_R40","doi-asserted-by":"crossref","unstructured":"Burger H, van Tol H, Boersma AW, et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)\/ABCG2 drug pump. Blood. 2004;104:2940\u20132942.","DOI":"10.1182\/blood-2004-04-1398"},{"key":"2019111704083346700_R41","doi-asserted-by":"crossref","unstructured":"Scharenberg CW, Harkey MA, Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood. 2002;99:507\u2013512.","DOI":"10.1182\/blood.V99.2.507"},{"key":"2019111704083346700_R42","doi-asserted-by":"crossref","unstructured":"Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 2004;104:3739\u20133745.","DOI":"10.1182\/blood-2003-12-4276"},{"key":"2019111704083346700_R43","doi-asserted-by":"crossref","unstructured":"Holtz MS, Slovak ML, Zhang F, Sawyers CL, Forman SJ, Bhatia R. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood. 2002;99:3792\u20133800.","DOI":"10.1182\/blood.V99.10.3792"},{"key":"2019111704083346700_R44","doi-asserted-by":"crossref","unstructured":"Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99:319\u2013325.","DOI":"10.1182\/blood.V99.1.319"},{"key":"2019111704083346700_R45","doi-asserted-by":"crossref","unstructured":"Talpaz M, Estrov Z, Kantarjian H, Ku S, Foteh A, Kurzrock R. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. J Clin Invest. 1994;94:1383\u20131389.","DOI":"10.1172\/JCI117473"},{"key":"2019111704083346700_R46","doi-asserted-by":"crossref","unstructured":"Chu S, Holtz M, Gupta M, Bhatia R. BCR\/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood. 2004;103:3167\u20133174.","DOI":"10.1182\/blood-2003-04-1271"},{"key":"2019111704083346700_R47","doi-asserted-by":"crossref","unstructured":"Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem. 1994;269:22925\u201322928.","DOI":"10.1016\/S0021-9258(17)31596-X"},{"key":"2019111704083346700_R48","doi-asserted-by":"crossref","unstructured":"Holyoake T, Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood. 1999;94:2056\u20132064.","DOI":"10.1182\/blood.V94.6.2056"},{"key":"2019111704083346700_R49","doi-asserted-by":"crossref","unstructured":"Bueno-da-Silva AE, Brumatti G, Russo FO, Green DR, Amarante-Mendes GP. Bcr-Abl-mediated resistance to apoptosis is independent of constant tyrosine-kinase activity. Cell Death Differ. 2003;10:592\u2013598.","DOI":"10.1038\/sj.cdd.4401210"},{"key":"2019111704083346700_R50","doi-asserted-by":"crossref","unstructured":"Ramaraj P, Singh H, Niu N, et al. Effect of mutational inactivation of tyrosine kinase activity on BCR\/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors. Cancer Res. 2004;64:5322\u20135331.","DOI":"10.1158\/0008-5472.CAN-03-3656"},{"key":"2019111704083346700_R51","doi-asserted-by":"crossref","unstructured":"Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925\u2013932.","DOI":"10.1182\/blood.V96.3.925"},{"key":"2019111704083346700_R52","doi-asserted-by":"crossref","unstructured":"Wolff NC, Veach DR, Tong WP, Bornmann WG, Clarkson B, Ilaria RL, Jr. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Blood. 2005;105:3995\u20134003.","DOI":"10.1182\/blood-2004-09-3534"},{"key":"2019111704083346700_R53","doi-asserted-by":"crossref","unstructured":"Kantarjian H, O\u2019Brien S, Cortes J, et al. Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications. Cancer. 2003;98:81\u201385.","DOI":"10.1002\/cncr.11477"},{"key":"2019111704083346700_R54","doi-asserted-by":"crossref","unstructured":"Avery S, Nadal E, Marin D, et al. Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib. Leuk Res. 2004;28 Suppl 1:S75\u201377.","DOI":"10.1016\/j.leukres.2003.10.019"},{"key":"2019111704083346700_R55","doi-asserted-by":"crossref","unstructured":"Alimena G, Breccia M, Mancini M, et al. Biclonal blast crisis with a mutated ABL catalytic domain in a Ph, del (9q)-positive CML patient responsive to imatinib: drug resistance should be monitored in all patients irrespective of response status. Leukemia. 2005;19:287\u2013289.","DOI":"10.1038\/sj.leu.2403584"},{"key":"2019111704083346700_R56","doi-asserted-by":"crossref","unstructured":"Cullis JO, Marks DI, Schwarer AP, et al. Relapse into blast crisis following bone marrow transplantation for chronic phase chronic myeloid leukaemia: a report of five cases. Br J Haematol. 1992;81:378\u2013382.","DOI":"10.1111\/j.1365-2141.1992.tb08243.x"},{"key":"2019111704083346700_R57","doi-asserted-by":"crossref","unstructured":"Branford S, Rudzki Z, Parkinson I, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood. 2004;104:2926\u20132932.","DOI":"10.1182\/blood-2004-03-1134"},{"key":"2019111704083346700_R58","doi-asserted-by":"crossref","unstructured":"Marin D, Kaeda J, Szydlo R, et al. Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia. 2005;19:507\u2013512.","DOI":"10.1038\/sj.leu.2403664"},{"key":"2019111704083346700_R59","doi-asserted-by":"crossref","unstructured":"Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423\u20131432.","DOI":"10.1056\/NEJMoa030513"},{"key":"2019111704083346700_R60","doi-asserted-by":"crossref","unstructured":"Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530\u20133539.","DOI":"10.1182\/blood.V99.10.3530"},{"key":"2019111704083346700_R61","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, Cortes J, O\u2019Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002;99:3547\u20133553.","DOI":"10.1182\/blood.V99.10.3547"},{"key":"2019111704083346700_R62","doi-asserted-by":"crossref","unstructured":"Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876\u2013880.","DOI":"10.1126\/science.1062538"},{"key":"2019111704083346700_R63","doi-asserted-by":"crossref","unstructured":"Liu NS, O\u2019Brien S. Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemia. Leuk Lymphoma. 2002;43:2413\u20132415.","DOI":"10.1080\/1042819021000040152"},{"key":"2019111704083346700_R64","doi-asserted-by":"crossref","unstructured":"O\u2019Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65:4500\u20134505.","DOI":"10.1158\/0008-5472.CAN-05-0259"},{"key":"2019111704083346700_R65","doi-asserted-by":"crossref","unstructured":"Hochhaus A. Cytogenetic and molecular mechanisms of resistance to imatinib. Semin Hematol. 2003;40:69\u201379.","DOI":"10.1053\/shem.2003.50045"},{"key":"2019111704083346700_R66","doi-asserted-by":"crossref","unstructured":"Giles FJ, Cortes JE, Kantarjian HM, O\u2019Brien SM. Accelerated and blastic phases of chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004;18:753\u2013774, xii.","DOI":"10.1016\/j.hoc.2004.03.005"},{"key":"2019111704083346700_R67","doi-asserted-by":"crossref","unstructured":"Sacchi S, Kantarjian HM, O\u2019Brien S, et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer. 1999;86:2632\u20132641.","DOI":"10.1002\/(SICI)1097-0142(19991215)86:12<2632::AID-CNCR7>3.0.CO;2-A"},{"key":"2019111704083346700_R68","doi-asserted-by":"crossref","unstructured":"Kell WJ, Burnett AK, Chopra R, et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood. 2003;102:4277\u20134283.","DOI":"10.1182\/blood-2003-05-1620"},{"key":"2019111704083346700_R69","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, O\u2019Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18:547\u2013561.","DOI":"10.1200\/JCO.2000.18.3.547"},{"key":"2019111704083346700_R70","doi-asserted-by":"crossref","unstructured":"Takayama N, Sato N, O\u2019Brien SG, Ikeda Y, Okamoto S. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol. 2002;119:106\u2013108.","DOI":"10.1046\/j.1365-2141.2002.03881.x"},{"key":"2019111704083346700_R71","doi-asserted-by":"crossref","unstructured":"Wolff NC, Richardson JA, Egorin M, Ilaria RL, Jr. The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr\/Abl-induced leukemia. Blood. 2003;101:5010\u20135013.","DOI":"10.1182\/blood-2002-10-3059"},{"key":"2019111704083346700_R72","doi-asserted-by":"crossref","unstructured":"Leis JF, Stepan DE, Curtin PT, et al. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma. 2004;45:695\u2013698.","DOI":"10.1080\/10428190310001625728"},{"key":"2019111704083346700_R73","doi-asserted-by":"crossref","unstructured":"Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 1998;338:962\u2013968.","DOI":"10.1056\/NEJM199804023381405"},{"key":"2019111704083346700_R74","doi-asserted-by":"crossref","unstructured":"Weisdorf DJ, Anasetti C, Antin JH, et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood. 2002;99:1971\u20131977.","DOI":"10.1182\/blood.V99.6.1971"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2005\/1\/188\/645173\/188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2005\/1\/188\/645173\/188.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T06:39:49Z","timestamp":1626763189000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2005\/1\/188\/19284\/Pathobiology-of-Lymphoid-and-Myeloid-Blast-Crisis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,1]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2005.1.188","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,1]]}}}